Current Report Filing (8-k)
February 09 2016 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported): |
|
February 9, 2016 |
STAAR Surgical
Company
__________________________________________
(Exact name of registrant as specified in
its charter)
|
|
|
Delaware |
0-11634 |
95-3797439 |
(State or other jurisdiction |
(Commission |
(I.R.S. Employer |
of incorporation) |
File Number) |
Identification No.) |
|
|
|
1911 Walker Ave, Monrovia, California |
|
91016 |
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
Registrant’s telephone number, including area code: |
|
626-303-7902 |
Not Applicable
______________________________________________
Former name or former address, if changed
since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
7.01 Regulation FD Disclosure.
STAAR
Surgical Company issued a press release regarding a cooperation agreement with a customer, Memira Holding
AB-SE. A copy of the press release is furnished as Exhibit 99.1 to this Report, and is incorporated herein by this
reference.
The
information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release dated February 9, 2016. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company |
|
February 9, 2016 |
By: |
/s/ Caren Mason |
|
|
Caren Mason |
|
|
President and Chief Executive Officer |
Exhibit 99.1
STAAR Surgical Company and Memira Holding
Announce Cooperation Agreement for Memira’s Eye Clinics throughout Scandinavia
MONROVIA, CA, February 9, 2016---STAAR Surgical Company
(NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, and Memira
Holding, Sweden, today announced they have entered into an agreement effective January 1, 2016, to provide STAAR’s phakic
intraocular lenses (ICL) as a primary and premium option for refractive eye treatment.
“As the largest refractive eye surgery provider in Scandinavia
with close to 50 clinics and having completed over 400,000 refractive surgery procedures over the last 25 years; we are very pleased
to join with STAAR to provide our patients seeking to reduce or correct myopia, hyperopia and astigmatism with an outstanding vision
care treatment in the CentraFLOW® ICL. It is our intention to partner with STAAR in building a clinical data repository, participating
in new product testing, providing excellent training and certification for our surgeons, placing the ICL as a primary vision treatment
and delivering value pricing for our patients. Our plans are to continue to expand our vision treatment services and we believe
STAAR will be an excellent partner to work with us to achieve our objectives, said Michael Lagerbäck, COO of Memira.”
“STAAR is pleased to have entered
into a strategic cooperation agreement with Memira where the CentraFLOW Visian implantable Collamer® lens will be positioned
as a primary and premium vision correction solution for their patients. In partnership with our distributor Alyko Medical, we have
committed to provide Memira with close cooperation including technical, marketing, clinical and educational programs to drive the
further growth of the ICL. STAAR considers cooperation and strategic agreements as fundamental to its transformational goal to
closely align with its customers to create an outstanding vision care experience and outcome for patients with essential clinical
validation as a core tenet,” said Caren Mason, President & CEO of STAAR.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery
for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or “ICL”. More than 550,000 Visian ICLs have been implanted
to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 employees and markets lenses in over
60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA.
For more information, please visit the Company’s website at www.staar.com.
Safe Harbor
All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: statements regarding proposed
prospective products current or future and any statements of assumptions underlying any of the foregoing. Important factors that
could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company’s
Annual Report on Form 10-K for the year ended January 2, 2015, under the caption “Risk Factors”, which is on file with
the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website
under the heading “SEC Filings.”
These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.
CONTACT: |
Investors |
Media |
|
EVC Group |
EVC Group |
|
Brian Moore, 310-579-6199 |
Dave
Schemelia, 646-445-4800 |
|
Doug Sherk, 415-652-9100 |
|
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Sep 2024 to Oct 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Oct 2023 to Oct 2024